Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vancomycin Exposure, Nephrotoxicity, and Sepsis Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

NCT07893223 is registered in ClinicalTrials.gov with Nutromics as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07893223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Vancomycin Exposure, Nephrotoxicity, and Sepsis Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
Lead sponsor
Nutromics
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2028
Enrollment
200 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Cohort 1

    Hospitalised participants receiving vancomycin (Vancomycin monitoring)

  • Cohort 2

    Hospitalised participants not receiving vancomycin (Biomarker Monitoring)

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Accuracy of Device-measured vancomycin ISF concentration vs. paired serum concentration Up to 5 Days

    Comparison of vancomycin concentration-time profiles and pharmacokinetic parameters (Cmax, Tmax, Cmin, AUC0-24) derived from interstitial fluid (Sensor Device) against paired serum vancomycin immunoassay results.

  • Accuracy of Device-measured biomarker (creatinine, C-reactive protein, lactate) ISF concentration vs. paired serum concentration Up to 5 days

    Determination of accuracy between Device-reported biomarker values and paired serum immunoassay results.

  • Relationship between ISF analyte concentrations and clinical outcomes Through 30 days after study completion

    Descriptive summary of association between ISF concentration profiles (vancomycin, creatinine, C-reactive protein, lactate) and 30-day clinical outcomes (discharge/readmission, morbidity, mortality, treatment-emergent adverse events).

  • General performance characterisation of the Device Up to 5 days

    Paired precision between simultaneously worn devices; device accuracy throughout wear duration; electrochemical sensor quality metrics.

Similar trials

Same condition (Acute Kidney Injury) and phase, most recent start first.